TrialOncoimmunology2026

A mixed inflammatory peripheral signature defines clinical outcomes in a phase II trial combining pembrolizumab with paclitaxel and carboplatin in melanoma.

Caroline Lambert et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.